Background: Stroke is a condition with high morbidity and mortality, and 75% of stroke survivors lose their ability to work. Stroke is a burden to the family and society. The purpose of this study was to evaluate the effectiveness of Chinese herbal patent medicines in the treatment of patients after the acute phase of a stroke.
Introduction
Worldwide, ischemic stroke is the second largest cause of death, and stroke from all causes has high morbidity and mortality. [1] Annually, 15 million people suffer a stroke. [2] In China, there are 2.5 million new stroke cases each year and 7.5 million stroke survivors. [3] Survivors may be affected by complications, including vascular dementia and hemiplegia.
The stroke recovery period occurs after the acute stroke period. Although mortality is low during the recovery period, there are serious functional neural defects and a high rate of stroke recurrence. Seventy-five percent of stroke survivors are unable to work. [4] The recurrence rate, 90 days after the stroke, is 7.4%, and the incidence rate of transient ischemic attacks is 17.3%. [5, 6] Stroke is a burden for the family and society.
Traditional Chinese Medicine (TCM) has been historically used for stroke treatment, and is widely used today. [7] Chinese herbal medicine is an important component of TCM, which has several characteristics, including natural medicine, complex composition, and multifunction.
Chinese herbal medicines for stroke treatment are generally a mixture of different plant and animal extracts. [8] Different herbal medicines have anti-inflammatory or antioxidant properties, cause vasodilation, increase cerebral blood flow velocity, inhibit platelet aggregation, protect against reperfusion injury, and increase tissue tolerance to hypoxia.
The role of herbal drug treatment for stroke recovery has been investigated. For example, YinxingDamo injection (including Ginkgo extract) was proposed to increase cerebral collateral circulation and capillary networks, while decreasing edema, intracranial pressure, and hypoxia-induced nerve cell injury. [10, 11] In areas of cerebral ischemia, Tongxinluo capsules (including, extract of ginseng and hirudo) may protect nerve cells by increasing the expression of brain-derived neurotrophic factors. [12, 13] Danhong injection (including Salvia miltiorrhiza and Carthamustinctorius) may upregulate the expression of growth-associated protein 43, promote axonal regeneration, and accelerate neural functional recovery. [14, 15] Although Chinese herbal medicine is widely used in stroke recovery in Southeast Asia and Chinese-speaking regions, the evidence of its efficacy remains insufficient. Additionally, there are various types and combinations of Chinese drugs on the market, and it is difficult to compare their therapeutic effects in clinical studies.
Although there have been systematic reviews of TCM treatments for stroke recovery in Chinese journals, the studies showed contradictory results. [16] [17] [18] A recent systematic review analyzed the effect of NeuroAiD (MLC601) treatment in stroke recovery and indicated that MLC601 has limited therapeutic effect on neural functional recovery when compared with placebo. [19] We analyzed the use of Chinese patent herbal medicines for stroke recovery. We used traditional and network meta-analysis to analyze the effect of Chinese herbal medicines on poststroke assessment outcomes.
Methods
This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. [20] 
Search strategy
We systematically searched, through August 2016, the following databases: PubMed, Embase, Cochrane Central Register of Controlled Trials, China Knowledge Resource Integrated Database (CNKI), China Science Periodical Database (CSPD), and China Biology Medicine disc (CBMdisc). Keywords used in the search including "post stroke," "stroke recovery," "convalescence," "Chinese herbal medicine," and "random." The details of the search strategy in PubMed are presented in Supplemental 1, Figure 1 . PRISMA flowchart illustrating the selection of studies included in our analyses. PRISMA = Preferred Reporting Items for Systematic Reviews and Metaanalyses.
Han et al. Medicine (2017) 96:49 Medicine Table 1 Characters of included studies. Table 2 Detail of risk of bias for each included study. Hirozo Goto [29] 2011 Random number [30] 1997 No information Liu Guang [31] 2003 No information Huang Jianjun [32] 2005 Random number [36] 2011 Random number [38] 2014 No information Yao Lifeng [39] 2010 No information Cao Xiaolan [40] 2012 Random number [44] 2008 No information Mai Lisha [45] 2006 Random number [46] 2013 No information Lin Xiaolin [47] 2013 No information Zheng Xiaolong [50] 2008 No information http://links.lww.com/MD/C4. The search was limited to studies published in English or Chinese. To identify additional eligible studies, we also manually searched reference lists from relevant original and review articles.
Data selection, data extraction, and quality assessment
Two authors independently searched the literature and selected relevant studies. Inconsistencies were resolved by group discussion. Eligible studies met the following inclusion criteria: patients with a stroke were evaluated during recovery and convalescence; randomized controlled trial; investigated poststroke neurological function and ability to participate in activities of daily living, but not complications; the intervention group was treated with Chinese herbal patent medicines, while the control group did not receive Chinese herbal patent medicines; and the outcome assessments included neurological function and the ability to engage in activities of daily living. Additionally, we excluded letters, editorials, reviews, conference papers, nonhuman studies, and academic dissertations that had not been peer-reviewed.
The following items were extracted from the articles: first author, publication year, sample size, average age, sex ratio, type of stroke, duration of stroke onset, interventions, control, duration of therapy, and follow-up. We assessed the methodological quality of the trials using the risk of bias approach according to the Cochrane Collaboration. [21] The data extraction and quality assessment were conducted independently by 2 authors. In case of disagreement, an additional author examined the original article and made an independent assessment.
The primary outcome of our analyses was the number of patients showing significant improvement, as assessed by widely used stroke recovery criteria, or the number of patients able to resume self-care. The secondary outcomes were neurological function and the ability to engage in activities of daily living, as assessed by the neurological functional defect scores (NDS), Barthel index (BI), Fugl-Meyer assessment (FMA), and functional independence measure (FIM). The major purpose of this study was to determine the effect of Chinese medicine on poststroke recovery of neurological function. We did not evaluate poststroke sequelae, including poststroke depression and epilepsy.
Statistical analysis
We performed a pairwise meta-analysis using a random-effects model. [22] For dichotomous outcomes, odds ratios (ORs), with 95% confidence intervals (CIs), were calculated to determine the effect size. For continuous data, the standard mean difference (SMDs) and 95% CIs were calculated. The I 2 statistic was used to assess heterogeneity across multiple studies. In the absence of statistical heterogeneity (<50%), we used a fixed-effect model, in the presence of heterogeneity we used a random-effects model. We used subgroup analysis to explore heterogeneity according to the drug delivery method and whether Chinese herbal patent medicines were or were not used in combination with acupuncture. Egger test [23] and Begg test [24] were used to evaluate publication bias. The symmetry of a funnel plot was assessed. The trim and fill method was used to correct for publication bias. [25] A random effects network meta-analysis for mixed multiple treatment comparisons was used to preserve the within-trial randomized treatment comparisons. [26] The network analysis adopted a frequentist framework, and a contrast-based model was used to evaluate multiarm trials. Transitivity was assessed by a [53] 2006 No information Niu Xiaoya [54] 2013 Random number network plot, which describes direct and indirect comparisons of any pair of interventions. Inconsistency between direct and indirect sources of evidence was statistically assessed globally (by comparison of the fit and parsimony of consistency and inconsistency models) and locally (by the calculation of the difference between direct and indirect estimates in all closed loops in the network). However, since there are no loops in the network, the network has no degrees of freedom for inconsistency. To rank the treatments for each outcome, we used the surface under the cumulative ranking (SUCRA) probabilities. [27] The comparisonadjusted funnel plots were used to determine whether small-study effects were present in our analyses. [28] All tests were 2-tailed, and a P value of less than .05 was considered statistically significant. Data analyses were performed using STATA software (version 13.0; StataCorp, College Station, TX).
Results
We identified 639 articles written in English and 972 written in Chinese. After removing duplicates, 968 articles were identified. After the titles and abstracts were screened, 874 articles were excluded. The full-text of the remaining 94 articles was evaluated, and 66 studies were excluded. Exclusion criteria were: the comparison group included herbal treatment (n = 20); treatment for complications (n = 9); acute stroke treatment (n = 9); use of nonpatented Chinese medicine formulae (n = 8); duplicate publications (n = 7); abstracts (n = 5); no desired outcomes (n = 5); protocols (n = 2); and master's thesis (n = 1). Finally, our systematic review included 28 trials that assessed 2780 patients (Fig. 1, Table 1 ). The age of patients ranged from 30 to 90 years. The number of male patients was slightly more than that of female patients. Eighteen studies included patients with ischemic stroke, 5 included patients with either hemorrhagic or ischemic stroke, and 5 did not specify the type of stroke. All studies included patients in the stroke recovery phase; however, 7 did not clearly define the duration of treatment. The shortest intervention and follow-up time was 2 weeks, and the longest was 180 days (Table 1) . Although all the studies were randomized controlled trials, 3 were of double-blind design. The overall quality of included studies was not considered ideal, and the details of risk of bias for each trial are shown in Table 2 . In the included studies, 1 received support from Moleac Pte. Ltd and the National Medical Research Council of Singapore. [35] One study received funding from Comprehensive Research on Aging and Health from the Japanese Ministry of Health, Labor, and Welfare. [29] In the other studies the funding source was not disclosed.
Chinese patent medicines were effective in recovery after stroke (OR, 3.03; 95% CI: 2.53-3.64; P < .001). In the drug-delivery subgroup analysis, oral Chinese medicine improved poststroke recovery (OR, 3.00; 95% CI: 2.37-3.80; P < .001), and intravenous injection of Chinese medicine had similar effects (OR, 3.14; 95% CI, 2.38-4.14; P < .001) (Fig. 2) . Chinese herbal medicines combined with acupuncture were more effective than (Fig. 3) . When assessing recovery of neurological function and the ability to perform activities of daily living, Chinese herbal patent medicines significantly improved the NDS scores when compared with control (SMD, À0.89; 95% CI, À1.44 to À0.35; P = .001). Chinese herbal patent medicines significantly improved scores on the BI (SMD, 0.73; 95% CI, 0.53-0.94; P < .001) and FMA (SMD, 0.6; 95% CI, 0.34-0.86; P < .001). In 1 study included in the analyses, the Chinese Medicine Symptom scores were significantly improved after herbal treatment (SMD, À0.95; 95% CI, À1.33 to À0.57; P < .001). No other significant differences were identified (Fig. 4) . Publication biases were identified in the overall effect results (Begg test, P = .035; Egger test, P = .074). After the correction with the trim and fill method, the results of the random effect model were unchanged. Other results did not show significant publication bias (Supplemental 2, http://links.lww.com/MD/C4).
In the network analysis, we compared Chinese herbal medicine plus acupuncture versus acupuncture alone, and Chinese herbal medicine versus placebo control. Comparisons of the therapeutic effectiveness of Chinese herbal patent medicines are shown in Fig. 5 . The figure identifies the predominantly pairwise comparisons of different Chinese patent medicines used for stroke recovery. The nodes were weighted according to the number of studies that evaluated each treatment, and the edges were weighted according to the precision of the direct estimate for each pairwise comparison. The comparisons of Chinese herbal medicines without acupuncture and with acupuncture are shown in Tables 3 and 4 , respectively. We ranked the comparative effects of all included Chinese patent medicines in stroke recovery with SUCRA probabilities (%). The results indicated that MLC601, Shuxuetong, and BuchangNaoxintong were most likely to improve stroke recovery in patients who did not receive acupuncture (Fig. 6A) . In addition, Mailuoning, Xuesaitong, and BuchangNaoxintong were more likely to improve stroke recovery when combined with acupuncture (Fig. 6B) . The comparison-adjusted funnel plot used to assess publication bias and determine the presence of small-study effects, did not identify publication bias in the network meta-analysis (Supplemental 2, http://links.lww.com/MD/C4).
Discussion
In this study, we systematically analyzed the effect of Chinese herbal patent medicine on the recovery of patients after a stroke and suggest that these medicines have a significant positive effect on stroke recovery. Chinese patent medicine significantly improved the neurological function defect scores, the BI scores, and the FMA. In general, the medicines were found to be effective for stroke recovery. The network meta-analysis showed that MLC601, Shuxuetong, and BuchangNaoxintong were most likely to facilitate stroke recovery without acupuncture, while EupolyphagaseuSteleophaga, CalculusBovis Artifactus, Buthusmartensii, and CornuSaigaetataricae). A recent meta-analysis including 4 randomized clinical trials suggested that MLC601 is not more effective than placebo in recovery after stroke [19] ; however, we found that MLC601 was likely to improve stroke recovery. The different results were likely because we excluded studies that included acute stage stroke treatment.
Shuxuetong injection, composed of hirudo and pberetima, is commonly used in TCM for the treatment of ischemic cerebrovascular events. Shuxuetong affects blood rheology, and may prolong clotting time, reduce platelet adhesion, increase arterial blood flow, and inhibit thrombosis. Shuxuetong inhibits BCL-2-associated X protein and caspase-3 induced nerve cell death by promoting BCL-2 expression. [57] In addition, Shuxuetong reduces inflammation as assessed by levels of highsensitivity C-reactive protein and homocysteine. [58] Hirudo and pberetima are widely used in traditional medicine to promote blood circulation and remove blood stasis.
The potential mechanisms were as follows: stroke is neurological condition resulting from local vascular abnormalities. Neural cells in the center of the injury region may suffer irreversible injury and cell death. Oxygen-free radicals are produced in the ischemic penumbra, and reperfusion of the area results in the death of additional neurons. The Chinese herbal medicines Honghua and Danshen, the main components in BuchangNaoxintong, are used clinically to activate blood circulation and dissipate blood stasis.
Nonpatented Chinese herbal medicines were also used to treat the complications of stroke. The most frequently used nonpatented Chinese herbal medicine was BuyangHuanwu Decoction, which contains ChuanXiongQin, Hunagqi, and other herbal components. [59] In the treatment of severely disabled patients, or invalids, the dose of Hunagqi is increased, which invigorates the distribution of medicines such as SanQi, HongHua, and Danshen. In this study the combination of Chinese patent medicines improved poststroke recovery in a manner similar to traditional Chinese medicines that were not patented.
Traditional Chinese medicine treatment of poststroke recovery has several challenges, including dialectical complexity, multiple prescriptions, and lack of uniformity of drugs. Therefore, we prefer to use standardized Chinese patent medicines to treat complications of stroke. There are few randomized clinical trials (RCTs) that have evaluated the combination of Chinese patent medicine on the treatment of stroke sequelae. Further clinical studies of Chinese medicine, using modern medical research methods, could provide more reliable results.
We analyzed the effectiveness of Chinese herbal patent medicines for stroke recovery by traditional meta-analysis. Our study suggests that Chinese herbal patent medicines promote functional neurological recovery after stroke. We performed subgroup analysis according to the method of drug delivery (oral or intravenous) and whether the Chinese herbal patent medicines were or were not combined with acupuncture. In our study, we could not conclude that oral administration is better than intravenous. However, because of the diverse and complex components of herbal medicines, intravenous injection may have a higher incidence of adverse reactions, while adverse reactions to oral drugs are uncommon. Chinese herbal medicines with or without acupuncture have similar results. Acupuncture-related randomized controlled trials are needed to confirm the effect of acupuncture on patients' poststroke.
We did not analyze stroke patients in acute phase because the main purpose of acute phase treatment is to reduce the mortality and disability rate. The purpose of acute phase treatment is to rapidly reduce intracranial pressure, reduce cerebral edema, prevent infection, and provide symptomatic treatment. Chinese herbal medicine is mainly used to protect nervous system function and is not the main treatment for an acute stroke.
The individualized treatment model, rather than the model generalized to the population, was always used for patients receiving Chinese herbal medicines. In the current study, the treatment effect was evaluated by comparing patients treated with Chinese herbal patent medicines with patients who did not receive Chinese herbal patent medicine. For other individualized treatments model was balanced between intervention and control group. Although potential confounders may influence the treatment effect, we describe a systematic and comprehensive review for the treatment effect of Chinese herbal medicines on poststroke recovery.
Chinese herbal medicine is the traditional medicine in China, and provides an important supplement in the treatment of stroke Table 3 The league table of the consistency model network meta-analysis for the therapeutic effectiveness of Chinese herbal patent medicines without acupuncture on post stroke recovery.
Buchang Naoxintong (69.2%) * Chinese medicines needs to be scientifically confirmed before international acceptance of these medicines occurs.
The double-blind randomized placebo-controlled study is an important study design to evaluate the effectiveness of medical interventions. In the past, Chinese scientists had a lower level of knowledge of study design, especially in tested patients. Thus, well-designed RCTs are not common in China. In addition, it is complicated to design a placebo control for Chinese medicine and other natural medicines. The color, smell, and taste are difficult to simulate with nontherapeutic ingredient. However, Chinese scientists have explored creating placebo herbal drugs. Dilution of the drugs or removal of the effective components can result in a placebo that retains the original appearance and smell, with minimal therapeutic effect. Placebo preparation of natural drugs for use in clinical trials is an urgent issue for Chinese scientists.
This study has several limitations. First, the results were based on previous studies, not on an individual patient level. Second, the outcome assessments have a relatively high degree of subjectivity. Third, due to the variety of herbal medicines, we Figure 6 . The cumulative ranking plots based on the estimated from SUCRA probabilities for overall effect. A, Without acupuncture. B, Combined with acupuncture. The cumulative ranking plots based on the estimated from SUCRA probabilities for major outcome. SUCRA that expresses the percentage of effectiveness each treatment was first compared with an ideal drug. The plot shows cumulative probabilities versus ranks for all treatments in network analysis. SUCRA = surface under the cumulative ranking. could not classify the drugs based on their composition. Fourth, we did not analyze Chinese medicine formulae and nonpatent drugs. Fifth, although some studies did not distinguish between ischemic or hemorrhagic stroke, treatment using TCM is relative similar for both types of stroke and is based on identifying TCM syndromes. Further studies are needed to clarify the effective ingredients of Chinese herbal medicine. Sixth, data from Taiwan, Japan, and Korea were not included due to language restricted. Seventh, the criteria for significant improvement were different among the included studies, this could introduce uncontrolled biases and affect treatment effect for poststroke recovery. Finally, we originally intended to evaluate subgroup analysis based on life style; however, these data were not available. The findings of this study indicate that the Chinese herbal patent medicines are effective for stroke recovery, and that MLC601, Shuxuetong, and BuchangNaoxintong are most likely to improve stroke recovery in patients not receiving acupuncture. In addition, Mailuoning, Xuesaitong, BuchangNaoxintong are most likely to improve stroke recovery in patients receiving acupuncture.
